论文部分内容阅读
目的:评价西宁地区高危冠脉综合征患者应用替罗非班的安全性和出血相关因素。方法:入选78例急性冠脉综合征患者使用替罗非班治疗,观察其出血情况,并与国内临床研究比较,分析出血相关危险因素。结果:9例急性冠脉综合征患者发生出血并发症(11.5%),其中轻度出血9例(11.5%),严重出血0例,血小板在原计数的基础上明显减少1例(1.3%),输血0例。与国内临床研究相比,轻度出血(10.3%和11.5%)(P>0.05),血小板减少症1例(1.2%和1.3%)(P>0.05)。多因素回归分析表明,年龄≥65岁(OR=2.53,P<0.01)、肾小球滤过率(GFR)≤60mL/min/1.73m2(OR=10.59,P<0.01),与出血并发症发生显著相关。结论:替罗非班的临床应用是安全的,其出血并发症发生率与国内、外研究相似;老年、肾功能不全是替罗非班治疗出血并发症增加的独立危险因素。
Objective: To evaluate the safety and bleeding related factors of tirofiban in patients with high-risk coronary syndrome in Xining area. Methods: A total of 78 patients with acute coronary syndrome were enrolled in this study. Tirofiban was used to treat the bleeding. The bleeding related factors were compared with those of the domestic clinical study. Results: The bleeding complication occurred in 9 patients (11.5%) with mild bleeding in 9 (11.5%), severe bleeding in 0, and platelet count in 1 (1.3%) on the basis of the original count. Transfusion in 0 cases. Compared with the domestic clinical study, mild bleeding (10.3% vs 11.5%) (P> 0.05) and thrombocytopenia (1.2% vs 1.3%) (P> 0.05). Multivariate regression analysis showed that GFR ≥60mL / min / 1.73m2 (OR = 10.59, P <0.01), with age ≥65 years (OR = 2.53, P <0.01) Significantly related. Conclusion: The clinical application of tirofiban is safe, and the incidence of bleeding complications is similar to that of domestic and foreign studies. Elderly and renal insufficiency are independent risk factors for the increased bleeding complications of tirofiban.